Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis

被引:6
|
作者
Omerzu, Tomaz [1 ]
Magdic, Jozef [1 ]
Hojs, Radovan [2 ,3 ]
Potocnik, Uros [2 ]
Gorenjak, Mario [2 ]
Fabjan, Tanja Hojs [1 ,2 ]
机构
[1] Univ Med Ctr Maribor, Dept Neurol, Ljubljanska 5, Maribor 2000, Slovenia
[2] Univ Maribor, Fac Med, Taborska Ulica 8, Maribor 2000, Slovenia
[3] Univ Med Ctr Maribor, Dept Nephrol, Clin Internal Med, Ljubljanska 5, Maribor 2000, Slovenia
关键词
Inflammation; Neuroimmunology; Carotid intima media thickness; Cystatin C; Interleukin  6; CAROTID-ARTERY ATHEROSCLEROSIS; DISABILITY PROGRESSION; FUNCTIONAL COMPOSITE; INFLAMMATION; DISEASE; RISK; COMORBIDITY; DIALYSIS; COMMON;
D O I
10.1007/s00508-021-01862-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Multiple sclerosis is an inflammatory disorder of the central nervous system. Inflammation may create high susceptibility to subclinical atherosclerosis. The purpose of this study was to compare subclinical atherosclerosis and the role of inflammatory cytokines between the group of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls matched for age and sex. Methods The study group consisted of 112 non-diabetic and non-hypertensive RRMS patients treated with disease modifying drugs (DMD) and the control group was composed of 51 healthy subjects. The common carotid artery (CCA) intima media thickness (IMT) was investigated. Serum levels of risk factors for atherosclerosis and inflammatory cytokines were also determined. Results The mean CCA IMT (0.572 +/- 0.131 mm vs. 0.571 +/- 0.114 mm) did not differ (p > 0.05) between patients and controls. The RRMS patients' CCA IMT was significantly correlated with serum interleukin 6 (IL-6) (p = 0.027), high-sensitivity C-reactive protein (hs-CRP) (p = 0.027), cystatin C (p < 0.0005), glucose (p = 0.031), cholesterol (p = 0.008), LDL (p = 0.021), erythrocyte sedimentation rate (p = 0.001) and triglyceride (p = 0.018) level. We fitted generalized linear models in order to assess the relationship between CCA IMT and IL-6 with adjustment for sex and age. The obtained results showed that adjusted for age (p < 0.001) and sex (p = 0.048) IL-6 serum levels statistically significantly (p = 0.009) predict CCA IMT only in the RRMS group. Conclusion The findings of the present study suggest that when treated with DMD RRMS might not be an independent risk factor for early atherosclerosis presenting with arterial wall thickening; however, the results suggest a significant association of IL-6 serum levels with CCA IMT only in the RRMS group.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 50 条
  • [21] Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis
    Pellizoni, Felipe Papa
    Leite, Aline Zazeri
    Rodrigues, Nathalia de Campos
    Ubaiz, Marcelo Jordao
    Gonzaga, Marina Ignacio
    Takaoka, Nauyta Naomi Campos
    Mariano, Vania Sammartino
    Omori, Wellington Pine
    Pinheiro, Daniel Guariz
    Matheucci Junior, Euclides
    Gomes, Eleni
    Oliveira, de Gislane Lelis Vilela
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (09)
  • [22] Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?
    Lis, Martyna
    Niedziela, Natalia
    Adamczyk-Zostawa, Jowita
    Wierzbicki, Krzysztof
    Czuba, Zenon
    Zalejska-Fiolka, Jolanta
    Bartman, Wojciech
    Swietek, Agata
    Adamczyk-Sowa, Monika
    BIOMEDICINES, 2024, 12 (07)
  • [23] Therapeutic Goals of Baseline and Escalation Therapy for Relapsing-Remitting Multiple Sclerosis
    Gold, R.
    Hartung, H. -P.
    Stangel, M.
    Wiendl, H.
    Zipp, F.
    AKTUELLE NEUROLOGIE, 2012, 39 (07) : 342 - 350
  • [24] Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis
    D'Amico, Emanuele
    Zanghi, Aurora
    Parrinello, Nunziatina Laura
    Romano, Alessandra
    Palumbo, Giuseppe Alberto
    Chisari, Clara Grazia
    Toscano, Simona
    Raimondo, Francesco Di
    Zappia, Mario
    Patti, Francesco
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis
    Tasset, Inmaculada
    Bahamonde, Carmen
    Agueera, Eduardo
    Conde, Cristina
    Cruz, Antonio H.
    Perez-Herrera, Aleyda
    Gascon, Felix
    Giraldo, Ana I.
    Ruiz, Maria C.
    Lillo, Rafael
    Sanchez-Lopez, Fernando
    Tunez, Isaac
    PHARMACOLOGICAL REPORTS, 2013, 65 (03) : 624 - 631
  • [26] Tracking successive Wallerian degenerations in a relapsing-remitting multiple sclerosis patient
    Hannoun, Salem
    Durand-Dubief, Francoise
    Roch, Jean-Amedee
    Sappey-Marinier, Dominique
    Cotton, Francois
    JOURNAL OF NEURORADIOLOGY, 2016, 43 (05) : 359 - 361
  • [27] Hyperreflective dots in the avascular outer retina in relapsing-remitting multiple sclerosis
    Schmidt, Mathias Falck
    Pihl-Jensn, Gorm
    Torm, Marie Elise Wistrup
    Passali, Moschoula
    Larsen, Michael
    Frederiksen, Jette Lautrup
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 72
  • [28] Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis
    Meuth, Sven G.
    Bittner, Stefan
    Seiler, Carola
    Goebel, Kerstin
    Wiendl, Heinz
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (02) : 198 - 203
  • [29] Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background
    Rito, Yamel
    Flores, Jesus
    Fernandez-Aguilar, Angeles
    Escalante-Membrillo, Carmen
    Barboza, Miguel A.
    Amezcua, Lilyana
    Corona, Teresa
    ACTA NEUROLOGICA BELGICA, 2018, 118 (01) : 47 - 52
  • [30] Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing-Remitting Multiple Sclerosis
    Escribano, Begona M.
    Aguilar-Luque, Macarena
    Bahamonde, Carmen
    Conde, Cristina
    Lillo, Rafael
    Sanchez-Lopez, Fernando
    Giraldo, Ana I.
    Cruz, Antonio H.
    Luque, Evelio
    Gascon, Felix
    Aguera, Eduardo
    Tunez, Isaac
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (31) : 4876 - 4880